Clarity

34% of Professional Investors Are Interested in Building Biodiversity-themed Financial Products

Retrieved on: 
Wednesday, July 19, 2023
Environment, Technology, Other Technology, Professional Services, Sustainability, Data Analytics, Data Management, Other Professional Services, Artificial Intelligence, GIST, Survival, Disclosure, World Wide Fund for Nature, Science, Index, Clarity, Biodiversity, ETF, Traction, Investment, Algorithm, ESG, PDF, SVP, Automation, Potential, Agriculture

The virtual event shed light on the substantial commitment of financial institutions to incorporate biodiversity into their decision-making processes .

Key Points: 
  • The virtual event shed light on the substantial commitment of financial institutions to incorporate biodiversity into their decision-making processes .
  • Notably, the 140 signatories of the Finance for Biodiversity initiative collectively manage an impressive $20 trillion in assets.
  • For users managing portfolios composed of multiple companies or funds, technology facilitates data aggregation from asset-level data to portfolio-level data.
  • The company remains dedicated to providing tools, data, and methodologies to empower investors to incorporate biodiversity considerations in a meaningful and impactful manner into portfolios, goal-setting and reporting.

Clarity AI: On average, companies in SDG funds sell less than 1% of their products and/or services in the countries that need them the most

Retrieved on: 
Monday, July 17, 2023
Sustainability, Environment, Environmental, Social and Governance (ESG), Environmental Policy, Climate Change, Professional Services, Technology, Other Technology, Clarity, Sustainable Development Goals, SDG, Research, Investment, Attention, Tourism, Transport

On average, companies in SDG funds sell only 1% of their products and services in these countries.

Key Points: 
  • On average, companies in SDG funds sell only 1% of their products and services in these countries.
  • The SDG Index, a valuable tool for evaluating countries' progress towards the SDGs, demonstrates that different countries are at varying stages of advancement towards achieving the SDG targets.
  • Furthermore, the distribution of revenues generated by companies in SDG funds does not align with the needs of countries lagging in SDG progress.
  • On average, companies in SDG funds receive more than 75% of their revenues from countries in the top quartile of the SDG Index, indicating a flow of funds to already well-performing nations.

Clarity AI: ESG Controversies Led to a 2% to 5% Stock Underperformance after Six Months

Retrieved on: 
Wednesday, July 12, 2023
Environment, Technology, Finance, Professional Services, Software, Sustainability, Data Analytics, Data Management, Environmental, Social and Governance (ESG), Artificial Intelligence, Natural language processing, Ethics, High, ESG, Clarity, Controversy, Research, Attention, Risk, Classification, Mining, Risk management

ESG-related controversial incidents often receive significant attention from the media but the link between these controversies and actual stock performance isn’t always clear.

Key Points: 
  • ESG-related controversial incidents often receive significant attention from the media but the link between these controversies and actual stock performance isn’t always clear.
  • Analysis by Clarity AI , the global sustainability technology platform, tests the hypothesis that involvement in ESG Controversies is a valid predictor of corporate medium-term value loss.
  • The legal and regulatory consequences of such incidents can also be expensive and time-consuming to resolve, further damaging the company's reputation and market value.
  • In general, higher severity incidents led to larger deltas in company value when compared to lower severity cases.

Diligent Data Launches ESG Module, Empowering Organizations to Benchmark ESG Efforts Against Industry Peers

Retrieved on: 
Monday, June 26, 2023
Professional Services, Environmental, Social and Governance (ESG), Data Analytics, Environment, Technology, Sustainability, Software, GRC, Organization, Clarity, S, Risk, Climate, ESG, News, Asset management, Risk management, Diligence

“Pressure is mounting on organizations to enhance their ESG disclosures, with twenty-six environmental and social proposals winning majority support at S&P 500 companies in 2022, compared to eighteen in 2020,” said Amanda Carty, Managing Director of ESG & Data Intelligence at Diligent.

Key Points: 
  • “Pressure is mounting on organizations to enhance their ESG disclosures, with twenty-six environmental and social proposals winning majority support at S&P 500 companies in 2022, compared to eighteen in 2020,” said Amanda Carty, Managing Director of ESG & Data Intelligence at Diligent.
  • “Consequently, we’ve heard from our customers that being able to compare climate posture to their peers is becoming increasingly valuable.
  • Diligent offers ESG scores for over 15,000 organizations worldwide, calculated using Clarity AI’s proprietary methodology based on data from public disclosures and 30+ external data partners.
  • “We’re thrilled to partner with Diligent, a leader in GRC software, to bring Clarity AI’s market-leading ESG scores to its customers.”

FDA ADVISORY COMMITTEE UNANIMOUSLY CONFIRMS EFFICACY AND CLINICAL BENEFIT OF LEQEMBI FOR EARLY ALZHEIMER'S DISEASE

Retrieved on: 
Friday, June 9, 2023
Amyloid-related imaging abnormalities, Priority review, The New England Journal of Medicine, Doctor of Public Health, HIV/AIDS, Hobby, Optimism, CMS, Network, Centers for Medicare & Medicaid Services, Alzheimer's Association, Advisory Committee, Cancer, Multimedia, Oncology Drug Advisory Committee, Medicare, Clarity, Food and Drug Administration Amendments Act of 2007, Dementia, ARIA, Patient, Physician, Pike, Diagnosis, Helpline, FDA, Treatment, Food, Disease, Pharmaceutical industry, Residential care, Alzheimer's disease

"The Alzheimer's Association welcomes and celebrates this action by the FDA Advisory Committee to support traditional approval of Leqembi for people with early Alzheimer's," said Joanne Pike, DrPH, Alzheimer's Association president and CEO.

Key Points: 
  • "The Alzheimer's Association welcomes and celebrates this action by the FDA Advisory Committee to support traditional approval of Leqembi for people with early Alzheimer's," said Joanne Pike, DrPH, Alzheimer's Association president and CEO.
  • The Alzheimer's Association and members of the Association's Early Stage Advisory Group each submitted comments urging the Advisory Committee to recommend traditional approval of Leqembi, which was granted accelerated approval in January 2023.
  • "We are in full agreement with the FDA Advisory Committee that Leqembi provides clinical benefit and that this benefit outweighs the risks.
  • Leqembi, an anti-amyloid treatment, changes the course of Alzheimer's and delivers clear clinical benefit for people in the early stages of the disease.

Marketing Authorisation Application for lecanemab submitted in Great Britain: BioArctic

Retrieved on: 
Monday, May 22, 2023
CET, Health care, Lecanemab, Brain, Clarity, Eisai, Co-promotion, Marketing Authorisation Application, MAA, Innovation, AD, Neurotoxicity, MHRA, Disease, Pharmaceutical industry, Biogen

Lecanemab has been designated by the MHRA for the Innovative Licensing and Access Pathway (ILAP).

Key Points: 
  • Lecanemab has been designated by the MHRA for the Innovative Licensing and Access Pathway (ILAP).
  • Lecanemab selectively binds and eliminates soluble, toxic Aβ aggregates (protofibrils) that are thought to contribute to the neurotoxicity in AD.
  • The Clarity AD study of lecanemab met its primary endpoint and all key secondary endpoints with highly statistically significant results.
  • BioArctic has the right to commercialize lecanemab in the Nordic region and currently Eisai and BioArctic are preparing for a joint commercialization in the region.

Marketing Authorisation Application for lecanemab submitted in Great Britain: BioArctic

Retrieved on: 
Monday, May 22, 2023
CET, Health care, Lecanemab, Brain, Clarity, Eisai, Co-promotion, Marketing Authorisation Application, MAA, Innovation, AD, Neurotoxicity, MHRA, Disease, Pharmaceutical industry, Biogen

Lecanemab has been designated by the MHRA for the Innovative Licensing and Access Pathway (ILAP).

Key Points: 
  • Lecanemab has been designated by the MHRA for the Innovative Licensing and Access Pathway (ILAP).
  • Lecanemab selectively binds and eliminates soluble, toxic Aβ aggregates (protofibrils) that are thought to contribute to the neurotoxicity in AD.
  • The Clarity AD study of lecanemab met its primary endpoint and all key secondary endpoints with highly statistically significant results.
  • BioArctic has the right to commercialize lecanemab in the Nordic region and currently Eisai and BioArctic are preparing for a joint commercialization in the region.

Clarity AI: 44% of Professional Investors Are Now Using Sustainability Analytic Capabilities or Data from Multiple Service Providers

Retrieved on: 
Thursday, May 18, 2023
Banking, Software, Professional Services, Data Management, Technology, Asset Management, Artificial Intelligence, Data Analytics, Legal, Insurance, Finance, Environmental, Social and Governance (ESG), Consulting, Clarity, ESG, Asset, Wealth management, Investment, Workflow, Asset management, Retail

44% of professional investors are now using sustainability analytic capabilities or data from multiple service providers, suggesting market participants are looking for a greater number of higher quality solutions when it comes to analyzing the sustainability of their portfolios, according to a new survey by Clarity AI.

Key Points: 
  • 44% of professional investors are now using sustainability analytic capabilities or data from multiple service providers, suggesting market participants are looking for a greater number of higher quality solutions when it comes to analyzing the sustainability of their portfolios, according to a new survey by Clarity AI.
  • Clarity AI , the leading sustainability tech platform, conducted a market survey of over 160 professional investors, including Asset Managers, Wealth Managers, and Asset Owners in Europe and North America, to gain insights into the investment priorities and preferences of investors with regards to sustainability.
  • 44% of that same cohort are currently buying sustainability analytic capabilities or data from more than one service provider.
  • In addition, 81% of respondents are open to switching sustainability analytics or data vendors.

Diligent Showcase Launches to Connect Customers with Partners, Integrations and Services to Enhance Their GRC and ESG Programs

Retrieved on: 
Wednesday, May 17, 2023
Software, Environmental, Social and Governance (ESG), Artificial Intelligence, Data Management, Professional Services, Technology, Security, Business, Software as a service, S&P Global, GRC, BIG, Partner, Design Worldwide Partnership, DFIN, Consultant, Corporation Service Company, Organization, Clarity, BitSight, Donnelly (surname), Donnelley Financial Solutions, Risk, Showcase, ESG, SVP, Diligence

Diligent , the global leader in modern governance providing SaaS solutions across governance, risk, compliance, audit and ESG, today announces the launch of Diligent Showcase , a central hub for customers to enhance their GRC and ESG program with more than 50 partners and integrations.

Key Points: 
  • Diligent , the global leader in modern governance providing SaaS solutions across governance, risk, compliance, audit and ESG, today announces the launch of Diligent Showcase , a central hub for customers to enhance their GRC and ESG program with more than 50 partners and integrations.
  • The showcase features technology integrations, complementary solutions, and Diligent authorized service providers.
  • “Diligent Showcase makes it easy for our customers to quickly identify app integrations, solution providers, consultants and independent software vendors that are verified Diligent partners and best positioned to meet their unique business goals,” said Ricardo Moreno, SVP of Worldwide Partnerships at Diligent.
  • Using Diligent Showcase, customers can search Diligent’s expansive partner network by region or solution type to find the right partners, integrations, and content to help them tackle the evolving landscape of GRC and ESG.

Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease

Retrieved on: 
Tuesday, May 16, 2023
Priority review, The New England Journal of Medicine, Plaque, NDS, Alzheimer's disease, MHLW, Marketing, Neurotoxicity, Food, Advisory Committee, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Lecanemab, Ministry of Health, Labour and Welfare, Brain, Medication, Pharmaceuticals and Medical Devices Agency, Oncology Drug Advisory Committee, EMA, Clarity, Ministry, Eisai, The Different Forms of Flowers on Plants of the Same Species, Prescription Drug User Fee Act, PMDA, National Medical Products Administration, Co-promotion, PDUFA, Ministry of Health (Kuwait), MAA, AD, FDA, Phase, Health Canada, BLA, NMPA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disease, Medical imaging, Pharmaceutical industry, Biogen, Health

Lecanemab selectively binds and eliminates soluble, toxic Aβ aggregates (protofibrils) that are thought to contribute to the neurotoxicity in AD.

Key Points: 
  • Lecanemab selectively binds and eliminates soluble, toxic Aβ aggregates (protofibrils) that are thought to contribute to the neurotoxicity in AD.
  • As such, lecanemab may have the potential to have an effect on disease pathology and to slow down the progression of the disease.
  • The Clarity AD study of lecanemab met its primary endpoint and all key secondary endpoints with highly statistically significant results.
  • Lecanemab was approved under the accelerated approval pathway in the U.S. and was launched in the U.S. on January 18, 2023.